Skip to main content

Advertisement

Table 10 Differences in the approach to a third line treatment of CSU in physicians who do and do not follow the guidelines

From: Management of chronic spontaneous urticaria: a worldwide perspective

Treatment Compared groups n % (n) of physicians, who follow the guidelines % (n) of physicians, who don’t follow the guidelines X2 p
First-generation H1-antihistamines Administer 93 7.7 (80) 14.8 (13) 5.345 0.021
No 1033 92.3 (958) 85.2 (75)
Second-generation H1-antihistamines at standard dose Administer 78 6.9 (72) 6.8 (6) 0.002 0.967
No 1048 93.1 (966) 93.2 (82)
Updosed second-generation H1-antihistamines Administer 283 25.4 (264) 21.6 (19) 0.637 0.425
No 843 74.6 (774) 78.4 (69)
H2-antihistamines (e.g. famotidine or ranitidine) Administer 206 18.3 (190) 18.2 (16) 0.001 0.977
No 920 81.7 (848) 81.8 (72)
Ciclosporin Administer 254 23.1 (240) 15.9 (14) 2.416 0.120
No 872 76.9 (798) 84.1 (74)
Omalizumab Administer 570 51.8 (538) 36.4 (32) 7.764 0.005
No 556 48.2 (500) 63.6 (56)
Montelukast Administer 319 28.9 (300) 21.6 (19) 2.135 0.144
No 807 71.1 (738) 78.4 (69)
Dapsone Administer 91 7.8 (81) 11.4 (10) 1.384 0.239
No 1035 92.2 (957) 88.6 (78)
Systemic corticosteroids (for less than 10 days) Administer 227 20.1 (209) 20.5 (18) 0.005 0.943
No 899 79.9 (829) 79.5 (70)
Systemic corticosteroids (for more than 10 days in a row) Administer 146 12.7 (132) 15.9 (14) 0.733 0.392
No 980 87.3 (906) 84.1 (74)
Tricyclic antidepressants (e.g. doxepin) Administer 134 11.7 (121) 14.8 (13) 0.751 0.386
No 992 88.3 (917) 85.2 (75)
  1. Values marked in bold indicate a statistically significant difference (p < 0.05)